Merck Sharp + Dohme Corp.

Ra Pharmaceuticals, Inc.

Aurash Shahripour

Alexander Pasternak

Haifeng Tang

Shawn P Walsh

Barbara A Pio

Lihu Yang

Thomas Joseph Tucker

Alonso Ricardo

Elisabetta Bianchi

Yusheng Xiong

Angela Dawn Kerekes

Sookhee Nicole Ha

Nicolas Cedric Boyer

Raffaele Ingenito

Danila Branca

Hyewon Youm

Chengwei Wu

Willy Costantini

Yuping Zhu

Jessica Frie

Nardos H Teumelsan

Dooseop Kim

Eric J Gilbert

Zhi-Cai Shi

Zhong Ma

Mark W Embrey

Ketki Ashok Dhamnaskar

Kevin Michael Belyk

Alessia Santoprete

Brian Cato

Immacolata Conte

Stefania Colarusso

Reynalda Keh Dejesus

Derek M LaPlaca

Joseph R Stringer

Roberto Costante

Paul E Finke

Jinlong Jiang

Fa-Xiang Ding

Helen Y Chen

Harry R Chobanian

Xin Gu

Shuzhi Dong

Yan Guo

Timothy A Blizzard

Timothy Allen Blizzard

Qinghong Fu

Reynalda K DeJesus

Kevin M Belyk

Reynalda K Dejesus

Reynalda Keh De Jesus

Kevin Belyk

Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.

Cyclic polypeptides for PCSK9 inhibition

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure, kidney disease, edema, and conditions associated with excessive salt and water retention.

Inhibitors of the renal outer medullary potassium channel

This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.

This invention relates to compounds of Formula I-VI having the following general structure: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

Inhibitors of the Renal Outer Medullary Potassium channel

This invention relates to compounds having structural Formula (I); and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir 1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure. 

Growing community of inventors

Iselin, NJ, United States of America

Aurash Shahripour